MedTrace Logo

Sulforaphane to Reduce Symptoms of Schizophrenia

NCT02810964 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.

Conditions

Interventions

DRUG

Sulforaphane Nutraceutical

Sulforaphane Nutraceutical 6 tablets by mouth daily

DRUG

Identical-appearing Placebo

Identical-appearing Placebo 6 tablets by mouth daily

Sponsors & Collaborators

  • Sheppard Pratt Health System

    lead OTHER

Principal Investigators

  • Faith Dickerson, PhD, MPH · Sheppard Pratt Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-22
Primary Completion
2019-11-11
Completion
2019-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02810964 on ClinicalTrials.gov